4
Changes in Ownership
Summit Therapeutics Inc. Filed Acc 0000921895-20-003153
Chief Scientific Officer sold 43,282 shares at an average $4.41 ($190,694)
- Chief Scientific Officer acquired 43,282 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Powell David Jonathan Chief Scientific Officer | 2020-11-27 | Option exercise | +16,616 | $1.92 | $31,903 | 16,616 | D |
| Powell David Jonathan Chief Scientific Officer | 2020-11-27 | Option exercise | +12,953 | $1.79 | $23,186 | 29,569 | D |
| Powell David Jonathan Chief Scientific Officer | 2020-11-27 | Sale | −29,569 | $4.39 | $129,808 | 0 | D |
| Powell David Jonathan Chief Scientific Officer | 2020-11-30 | Option exercise | +13,713 | $1.79 | $24,546 | 13,713 | D |
| Powell David Jonathan Chief Scientific Officer | 2020-11-30 | Sale | −13,713 | $4.44 | $60,886 | 0 | D |
| Derivatives | |||||||
| Powell David Jonathan Chief Scientific Officer | 2020-11-27 | Option exercise · Stock Option (right to buy) | −16,616 | $1.92 | $31,903 | 417,639 | D |
| Powell David Jonathan Chief Scientific Officer | 2020-11-27 | Option exercise · Stock Option (right to buy) | −12,953 | $1.79 | $23,186 | 404,686 | D |
| Powell David Jonathan Chief Scientific Officer | 2020-11-30 | Option exercise · Stock Option (right to buy) | −13,713 | $1.79 | $24,546 | 390,973 | D |
| Open-market sales · 43,282 sh · avg $4.41 · $190,694 | |||||||
Loading xslF345X03/form412566003_12012020.xml…